ClinicalTrials.Veeva

Menu

Investigation of Vascular Relaxing Effects of Candesartan and Pioglitazone.

T

Technische Universität Dresden

Status

Completed

Conditions

Healthy Subjects

Treatments

Drug: Pioglitazone (drug) and/or candesartan (drug)

Study type

Interventional

Funder types

Other

Identifiers

NCT00154037
IKPD 02-05

Details and patient eligibility

About

The study is designed to test the hypothesis in healthy subjects that candesartan and pioglitazone provide additional vascular relaxing or modulating effects in addition to their blood-pressure and blood glucose level reducing ability, respectively.

Full description

The aim of the study is to investigate the effect of oral candesartan and/ or rosiglitazone therapy on the vascular responsiveness of different vasoactive compounds (angiotensin II, insulin, histamine and glyceroltrinitrate) in healthy subjects. Pioglitazone will be given orally (4 weeks 30mg/d, titrated to 45 mg/d for another 4 weeks). Candesartan will be given orally (4 weeks 8mg/d, titrated to 16 mg/d for another 4 weeks) as treatment. Every subject will receive intravenous stimulation with phenylephrine, angiotensin II, histamine, insulin and glyceroltrinitrate before and after an 8 weeks treatment interval with study medication or placebo. In addition, pulse wave velocity will me measured non-invasively before and after treatment.

Sex

Male

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Male
  • healthy
  • 18 - 40 years old
  • non-smoker
  • no additional medication

Exclusion criteria

  • any relevant disease
  • smokers
  • elevated liver enzymes
  • body weight different from Broca Norm > 20%
  • allergies

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems